Research Interest in Bevacizumab Remains Robust
Links shared publicly online about this topic.
- 0total visits
Research Interest in Bevacizumab Remains Robust
Despite controversy over its breast cancer approval status, bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the disease.
View full resource at onclive.com
Tags: Cancer, Breast Cancer, Colorectal Cancer Medication, Women's Health, Avastin, disease
Most Recently Shared on October 9, 2011 at 9:30 pm By:
RT @onclive: Bevacizumab (Avastin) remains at center stage of antiangiogenic therapies for #breastcancer http://ow.ly/6PQzY
Also Shared By:
Advertisement
Editor
@OncLive
Bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the #breastcancer http://ow.ly/6PQzY
1 year ago...